# Ryvu Therapeutics

Source: https://onco.cc/companies/ryvu-therapeutics/  
OnCo record `ryvu-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ryvu Therapeutics is a Poland-based biotechnology company running 5 late-stage cancer trials of RVU120, MEN1703 and Glofitamab in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and hodgkin lymphoma.

## Summary

Ryvu Therapeutics, based in Krakow, Poland, is a biotechnology company. A clinical-stage drug discovery and development company focused on novel small-molecule therapies addressing emerging targets in oncology. On ClinicalTrials.gov it is the lead sponsor of 5 recruiting or active phase 2 and phase 3 interventional cancer trials, testing RVU120, MEN1703, Glofitamab and Ruxolitinib in acute myeloid leukaemia, myelodysplastic syndromes / neoplasms, hodgkin lymphoma and myeloproliferative neoplasms. The largest, NCT06397313 (RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis), plans to enrol 230 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ryvu Therapeutics SA
- Tags: ctgov-sponsor
- HQ: Krakow
- Type: biotech
- Website: https://www.ryvu.com

## Sources

- Official website: https://www.ryvu.com
- ClinicalTrials.gov: trials led by Ryvu Therapeutics: https://clinicaltrials.gov/search?lead=Ryvu%20Therapeutics%20SA

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/)
- drugs: [MEN1703](https://onco.cc/drugs/men1703/), [RVU120](https://onco.cc/drugs/rvu120/)
- trials: [MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)](https://onco.cc/trials/nct06534437/), [RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms](https://onco.cc/trials/nct06243458/), [Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML](https://onco.cc/trials/nct06191263/)

---
JSON: https://onco.cc/api/v1/entities/ryvu-therapeutics.json